Key takeaway: Carrying a cancer‑linked gene increases risk but does not guarantee cancer because other inherited genes can modify its effect. A mouse study across four genetic backgrounds (581 liver tumors) exposed identical animals to the same carcinogen and found widely different outcomes: tumor onset ranged from 25 to 78 weeks, and about 95% of tumors had MAPK pathway mutations despite divergent susceptibility. These results help explain variable penetrance in humans (e.g., BRCA1/BRCA2) and support the use of polygenic risk scores to refine personalized risk.
Cancer Genes Aren't Destiny: How Your Whole Genome Shapes Cancer Risk
Magnified DNA Molecule and Double Helix Structure on a Minimalist Black Background illustrationalexokov on Magnific
We often hear that certain cancers "run in families," but inheriting a gene linked to cancer does not mean the disease is inevitable. Recent experimental work in mice shows that the effect of a single cancer‑promoting gene can be strongly modified by the rest of the genome — a phenomenon known as epistasis. In short: one gene’s impact can be altered, amplified or suppressed by other inherited variants.
The Mouse Experiment
To minimize the many confounding factors found in human studies (different diets, environments and genetic backgrounds), researchers repeated the initial steps of tumor formation hundreds of times across four genetically distinct groups of mice. The genetic differences between those groups were chosen to span the range seen in humans and, in one comparison, even exceeded it.
Every pup received a single dose of the same liver carcinogen at 15 days of age and was maintained in identical conditions. Investigators then sequenced DNA and measured gene activity in 581 liver tumors. If only the chemical exposure and random chance determined outcomes, tumors should have been similar across groups. They were not.
Tumor onset varied dramatically: in the most susceptible group tumors appeared as early as 25 weeks after exposure, whereas in the most resistant group onset was delayed to 78 weeks. Untreated animals developed spontaneous liver tumors following the same order of susceptibility. Under conditions that produced tumors in every animal of the most vulnerable group, many animals in the most resistant group never developed tumors.
Same Pathway, Different Outcomes
About 95% of the tumors carried an activating mutation in the MAPK signaling cascade, a pathway that helps control when liver cells divide and when they differentiate. The DNA sequence immediately surrounding these mutation sites was identical across groups for at least 13 bases on each side, so local sequence context did not explain the different outcomes.
Instead, the broader genetic background changed how many genetic "hits" were needed to start a tumor. The most susceptible mice typically required a single driver mutation; other groups usually needed two or more. In the most resistant group, over a third of tumors exhibited whole‑genome doubling during the first cell division after DNA damage — a fundamentally different route to malignancy. Identical exposure, identical target organ and pathway — yet different cancers, different timings, and sometimes no cancer at all.
Implications For Human Risk Prediction
These findings speak directly to how clinicians interpret genetic test results. A report that someone carries a "pathogenic variant" in a cancer gene is only one line in a much longer story. The variant matters, but so does the rest of the genome, family history and other inherited traits.
Clinical statistics already reflect this complexity. More than 60% of women who inherit a harmful BRCA1 or BRCA2 variant develop breast cancer in their lifetimes, compared with roughly 13% in the general population — leaving a substantial fraction of carriers who never develop the disease. Two people with the same BRCA1 change can therefore face very different lifetime risks depending on their broader inherited DNA.
Polygenic risk scores, which aggregate effects from many genetic variants across the genome, are already refining these risk estimates. The mouse study provides a mechanistic underpinning: the same driver mutation triggers different responses in cellular circuits that control division, differentiation, inflammation and death depending on genetic background. The mutation is constant; its consequences are not.
The Bigger Picture
Very few genes act in isolation or as absolute determiners. More commonly, inherited variants change the probability of disease — sometimes only a few percentage points, sometimes more than 50% — rather than guaranteeing an outcome. Understanding gene‑gene interactions helps explain why inheriting a so‑called "cancer gene" is usually a matter of elevated risk rather than destiny.
Originally published on Forbes.com
Note: This summary presents experimental findings in mice and their interpretation for human genetics. It does not replace personalized medical advice. Talk to a genetic counselor or clinician for individualized risk assessment.
Help us improve.
